Comparison of FDG and FAPI in Patients With Various Types of Cancer

Launched by THE FIRST AFFILIATED HOSPITAL OF XIAMEN UNIVERSITY · Jun 1, 2020

Keywords

ClinConnect Summary

This clinical trial is studying how well two different imaging tests can help detect cancer. The researchers want to compare a new type of scan called 68Ga-DOTA-FAPI-04 PET/CT with a more commonly used scan called 18F-FDG PET/CT. Both scans are used to find primary tumors and check if cancer has spread to other parts of the body. The goal is to see which scan might be better for identifying cancer in patients with various types of tumors.

To participate in this trial, you need to be an adult (18 years or older) with suspected or diagnosed cancer, and you must be scheduled to have both types of scans. It’s also important that you can provide consent for joining the study. However, people with non-cancerous tumors, those who are pregnant, or anyone unable to give consent cannot take part. If you join the study, you will undergo both scans, and your experiences will help researchers understand how these imaging tests can improve cancer diagnosis.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • (i) adult patients (aged 18 years or order); (ii) patients with suspected or newly diagnosed or previously treated malignant tumors (supporting evidence may include magnetic resonance imaging (MRI), CT, tumor markers and pathology report); (iii) patients who had scheduled both 18F-FDG and 68Ga-DOTA-FAPI-04 PET/CT scans; (iv) patients who were able to provide informed consent (signed by participant, parent or legal representative) and assent according to the guidelines of the Clinical Research Ethics Committee.
• Exclusion Criteria:
• • (i) patients with non-malignant lesions; (ii) patients with pregnancy; (iii) the inability or unwillingness of the research participant, parent or legal representative to provide written informed consent.